Roche Diagnostics China (hereinafter referred to as “Roche”) and Beijing Hotgene Biotechnology Co., Ltd. (hereinafter referred to as “Hotgene”) have reached a cooperation to jointly launch the novel coronavirus (2019-nCoV) antigenic detection kit on the basis of fully integrating the advantages of technology and resources of both sides, so as to meet the needs of the general public for antigenic detection under the new situation.
High quality diagnostic solutions are the foundation and core of Roche’s exploration of local innovation and cooperation. The COVID-19 antigen test kit launched in cooperation with Hotgene has passed strict product performance verification, and has been filed with the NMPA and obtained a medical device registration certificate. It has also been listed in the list of 49 approved COVID-19 antigen test kit manufacturers on the national register, fully guaranteeing the test quality, to help the general public accurately and quickly identify COVID-19 infection.
It is reported that this antigen detection kit adopts the double antibody sandwich method, which is suitable for in vitro qualitative detection of novel coronavirus (2019 nCoV) N antigen in nasal swab samples. Users can collect samples by themselves to complete sampling. The antigen detection has the advantages of strong anti-interference ability against common blocking drugs, high detection sensitivity, accuracy and short detection time. At the same time, the kit adopts a separate bagged design, which is convenient to carry around and can be used and tested immediately.
Based on the new changes in the current epidemic prevention and control, as well as the particularity of the use of the antigen detection kit and the applicable population, this COVID-19 antigen detection kit adopts the online sales mode to improve its accessibility. Relying on Roche’s existing online sales platform – Tmall’s online Store”, consumers can obtain this test kit more quickly and conveniently to achieve home self-health management.
Post time: Jan-09-2023
